Mark Lackner's Net Worth
$739 Thousand
Who is Mark Lackner?
Mark Lackner does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include IDEAYA Biosciences, Inc., and Zentalis Pharmaceuticals, Inc..
SEC CIK
Mark Lackner's CIK is 0001777413
Past Insider Trading and Trends
2021 was Mark Lackner's most active year for acquiring shares with 6 total transactions. Mark Lackner's most active month to acquire stocks was the month of January. 2021 was Mark Lackner's most active year for disposing of shares, totalling 11 transactions. Mark Lackner's most active month to dispose stocks was the month of January. 2020 saw Mark Lackner paying a total of $39,664.94 for 47,123 shares, this is the most they've acquired in one year. In 2020 Mark Lackner cashed out on 15,091 shares for a total of $115,967.49, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
IDEAYA Biosciences, Inc. (IDYA) Snapshot price: $36.21
SVP, Head BiologyMark Lackner used to own units in Common Stock but no longer holds any shares there. In the year 2019 Mark Lackner acquired a total of 10,623 shares in IDEAYA Biosciences, Inc. at a cost of $63,205.22, Mark also disposed a total of 12,469 shares of IDEAYA Biosciences, Inc. equalling to $204,177.74.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 24
| |||
Form 4
|
—
|
0
|
$14.01 | -$28,092.34 |
0
|
Scheduled
|
Feb 8 - Feb 10
| ||
Form 4
| -100.00% | -1.00K |
$12.43 | -$36,577.63 |
0
|
Scheduled
|
Jan 26
| ||
Form 4
|
—
|
0
|
$10.38 | -$68,523.42 |
0
|
Scheduled
|
Jun 16 - Jun 17
| ||
Form 4
| -100.00% | -845.00 |
$9.21 | -$7,779.13 |
0
|
Scheduled
|
Jun 2
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Zentalis Pharmaceuticals, Inc. (ZNTL) Snapshot price: $2.96
Chief Scientific OfficerMark Lackner owns 195,728 units of Common Stock which is worth $579,354.88. In the year 2024 Mark Lackner filed a total of 3 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +247.57% | 139.41K |
$11.54 | -$18,290.90 | 195.73K |
Feb 1 - Feb 2
| |||
Form 4
| +245.20% | 40K |
—
|
—
| 56.31K |
Jan 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||